VANCOUVER, British Columbia, July 06, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the "Company" or "Cannabix") developer of marijuana and alcohol breath testing technologies for workplace safety and law enforcement, announces detection of cocaine and its primary metabolite, benzoylecgonine, in human breath samples tested with the Marijuana Breath Test ("MBT"). Human breath samples were collected using the Cannabix Breath Collection Unit ("BCU") and were analyzed by Omega Laboratories Inc. ("Omega") utilizing liquid chromatography-mass spectrometry ("LC-MS").
Cocaine Detection in Breath Represents a Significant New Opportunity
Benzoylecgonine, the principal metabolite of cocaine, is routinely used by forensic and clinical laboratories to confirm cocaine exposure. The successful identification of both cocaine and benzoylecgonine demonstrates that the Cannabix MBT (consisting of the Cannabix BCU, disposable Breath Cartridges, and the Laboratory-Developed Test Method by Omega Laboratories) can capture these trace-level drug compounds from exhaled breath.
The Company believes these findings demonstrate application of the Cannabix MBT and the associated legally defensible chain of custody and analytical process beyond THC detection and allows for broader multi-drug breath testing applications for workplace safety, transportation, industrial, rehabilitation, and law enforcement markets.
Rav Mlait, CEO of Cannabix Technologies, stated, "Detecting cocaine and benzoylecgonine in human breath is significant because these compounds are exceptionally difficult to measure in breath. The concentrations are extremely low, making both breath collection and laboratory confirmation technically demanding."
Cocaine use is illegal and presents a significant safety concern in any industry.
Figure 1. Cannabix Marijuana Breath Test hardware including Breath Collection Unit (BCU) and Breath Cartridge (BC) technologies.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a leading developer of breath-based technologies designed to enhance public safety and reduce impairment-related risks in workplaces, law enforcement, and a range of different settings. The Marijuana Breath Test (MBT) targets delta-9 THC—the primary psychoactive compound in cannabis—in breath, providing a practical solution for identifying recent marijuana use.
The BreathLogix, unmanned alcohol screening solution supports organizations in proactively monitoring alcohol impairment, strengthening safety protocols, and promoting responsible behavior. By delivering innovative, non-invasive screening tools, Cannabix aims to help reduce accidents, improve decision-making, and protect organizations, individuals and the public at large. Visit www.cannabixtechnologies.com